The variant, a change in a single letter of the DNA sequence, impairs channels that control kidney function.
"It's not a heart gene," says Gerald W. Dorn II, MD, the Philip and Sima K. Needleman Professor of Medicine at Washington University School of Medicine in St. Louis and a lead investigator on the study. "It's a kidney gene. This protein is not even expressed in the heart. Nobody has previously considered that kidney-specific gene defects might predispose you to heart failure."
Heart failure is diagnosed when the heart can no longer provide sufficient blood to the body. It can have a number of causes, including high blood pressure, cancer therapy, viral infections of the heart or heart attack.
"It's a syndrome," Dorn says. "You've had sufficient damage to your heart that it doesn't work very well. You collect fluid in your lungs, you swell up, and you have trouble breathing."
The unexpected results highlight the advantage of performing genome-wide studies to find DNA sequence variants associated with disease.
"I was surprised by the finding," says Thomas P. Cappola, MD, assistant professor of medicine at the University of Pennsylvania School of Medicine, also a lead investigator on the study. "This is a good example of how taking unbiased approaches to study human disease can lead you to unexpected targets."
The study, a collaboration between Washington University School of Medicine, the University of Pennsylvania and other institutions, appears Jan. 17 in The Proceedings of the National Academy of Sciences.
In previous work, Dorn and colleagues used a partial genome-wide search technique to define the region of DNA in which sequence changes were associated with heart failure. But most of these sequence changes did not code for a change in protein and appeared not to have actually caused the increased risk. Instead, they served as markers, providing clues that this portion of the genome was worth a closer look.
"We said we've got the right ZIP code, but we're not on the right block," Dorn says.
So Dorn and his team sequenced the neighboring gene, looking for variations in parts of the DNA sequence that do code for proteins.
Studying three groups of Caucasian patients with heart failure, they found one DNA sequence variant that was common in all the groups and was actively involved in making an important protein for the body. A single change in the DNA sequence of a gene called CLCNKA leads to a change from arginine to glycine in the 83rd amino acid of the protein. This protein makes up part of a kidney channel responsible for controlling the secretion of chloride ions into the urine, an important process in maintaining the proper balance of salt and water in the body.
That single amino acid change reduced the channel's ability to shuttle chloride ions across the cell membrane by about half. Dorn hypothesizes that a result of this reduction could be elevated levels of a hormone called renin in the blood. Renin is produced in the kidney and is the first signal in a cascade that can damage the heart. This opens the possibility of helping people who have the variant reduce their risk of heart failure with drugs commonly used to treat high blood pressure, including ACE-inhibitors and aldosterone blockers.
To determine the effectiveness of this approach, Dorn and his colleagues have designed a clinical trial to be performed at Washington University and the University of Pennsylvania that will test whether effects of the risk gene can be opposed by an aldosterone blocker. If so, these findings open the door to tailored individual preventative therapy based on personal genotype, or "personalized medicine."
Over a lifetime, the average person has a one in five chance of developing heart failure. For individuals with one copy of the variant sequence, that risk may increase about 27 percent. For those who have two copies of the variant gene sequence, one from each parent, the risk of developing heart failure increases an estimated 54 percent. About one quarter of all Caucasians have two copies of the variant.
Dorn points out that having one or even two copies of this variant does not, in itself, cause heart failure.
"There are lots of people walking around with this variant who don't have heart failure," Dorn says. "But we think if you have this predisposition and something else happens to you, such as developing high blood pressure or having a small heart attack, that increases your odds of developing heart failure."
Cappola, TP, Matkovich, SJ, Wang W, van Booven D, Li M, Wang X, Qu L, Sweitzer NK, Fang JC, Reilly MP, Hakonarson H, Nerbonne JM, Dorn GW. Loss-of-function DNA sequence variant in the CLCNKA chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation. Proceedings of the National Academy of Sciences, Jan. 17, 2011.
This work was supported by National Institutes of Health and National Heart, Lung, and Blood Institute Cardiac Translational Implementation Program Grants, through the NIH Grand Opportunity component of the American Recovery and Reinvestment Act of 2009.
Washington University School of Medicine's 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation, currently ranked fourth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.
Joni Westerhouse | EurekAlert!
Complementing conventional antibiotics
24.05.2018 | Goethe-Universität Frankfurt am Main
Building a brain, cell by cell: Researchers make a mini neuron network (of two)
23.05.2018 | Institute of Industrial Science, The University of Tokyo
A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.
The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...
02.05.2018 | Event News
13.04.2018 | Event News
12.04.2018 | Event News
24.05.2018 | Ecology, The Environment and Conservation
24.05.2018 | Medical Engineering
24.05.2018 | Physics and Astronomy